Herb Garcinia Ineffective for Weight Loss
Herb Garcinia Ineffective for Weight Loss
February 1999; Volume 1: 24
Source: Heymsfield SB, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: A randomized controlled trial. JAMA 1998;280: 1596-1600.
Design and setting: Twelve-week randomized, double-blind, placebo-control-led trial in an outpatient weight control research unit in New York.
Subjects: 135 overweight men and women ages 18-65; mean BMI 32 kg/m2.
Treatment: Hydroxycitric acid (purported active ingredient in Garcinia cambogia) vs. placebo. Both groups were prescribed a high-fiber, low-energy diet (5040 kJ/d with 20% fat, 50% carbohydrate, and 30% protein).
Dose/Route/Duration: Two 500 mg caplets po tid taken 30 minutes before meals for 12 weeks. Total daily dose was 3000 mg herb containing 1500 mg hydroxycitric acid.
Outcome Measures: Body weight change and fat mass change.
Results: Patients in both groups lost weight, but there were no significant differences between the two groups. Reported adverse events were minor and not significantly different between the two groups.
Funding: NIH grants RR00645 and P30DK26687 and contract with Thompson Medical Company, manufacturer of products that include Garcinia.
Comments: Hydroxycitrate inhibits fatty acid synthesis, so there is a theoretical basis for possible efficacy, but this study demonstrates that Garcinia adds no benefit to a conventional weight loss plan. The authors note that their trial is longer than seven previous trials (all of which were four to eight weeks long, and five of which claimed a positive result for Garcinia). Additional comments on previous trials included the fact that five trials were not published in peer-reviewed journals and that five trials administered Garcinia with other potentially active ingredients, including chromium, caffeine, and L-carnitine.
This trial may be better than previously published trials, but limitations still exist, including lack of monitoring of diet compliance. Of most concern is the fact that only 62% of the subjects completed the trial. Although the dropouts appeared evenly divided between the two groups, inadequate information is provided about drop-outs—for 36 patients (27%) it is noted only that they were "lost to follow-up." In a long-term trial this may be more acceptable but that’s a lot of patients to disappear in a three-month trial.
All trials performed to date appear to have included a low-calorie diet; this is perhaps not an ideal circumstance in which to test a product that decreases lipid synthesis. It would be interesting to study if Garcinia has any effect when given to people who have not changed their diets.
February 1999; Volume 1: 24Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.